How to buy Neuren Pharmaceuticals (NEU) shares in Australia
Learn how to easily invest in Neuren Pharmaceuticals shares.
Neuren Pharmaceuticals is a biotechnology business based in Australia. Neuren Pharmaceuticals shares (NEU) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian dollars. Neuren Pharmaceuticals has a trailing 12-month revenue of around $78.3 million. If you're looking to buy shares, check out the steps below.
How to buy shares in Neuren Pharmaceuticals
- Compare share trading platforms. To buy shares listed in Australia, you'll need to sign up to a broker with access to the ASX. Our table can help you choose.
- Open and fund your brokerage account. Complete an application with your personal and financial details, such as your ID and tax file number. Fund your account with a bank transfer, PayPal or debit card.
- Search for Neuren Pharmaceuticals . Find the share by name or ticker symbol: NEU. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Neuren Pharmaceuticals reaches your desired price. Look into dollar-cost averaging to spread out your risk, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At today's price, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs.
- Check on your investment. Congratulations, you own a part of Neuren Pharmaceuticals . Optimise your portfolio by tracking how your stock and the business performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that affect your stock.
What's in this guide?
- Neuren Pharmaceuticals key stats
- Compare share trading platforms
- Is Neuren Pharmaceuticals stock a buy or sell?
- Neuren Pharmaceuticals performance over time
- Are Neuren Pharmaceuticals shares over-valued?
- Neuren Pharmaceuticals 's financials
- How volatile are Neuren Pharmaceuticals shares?
- Does Neuren Pharmaceuticals pay a dividend?
- Have Neuren Pharmaceuticals shares ever split?
- Other common questions
Neuren Pharmaceuticals stock price (ASX:NEU)Use our graph to track the performance of NEU stocks over time.
Neuren Pharmaceuticals shares at a glance
|52-week range||$6.72 - $15.53|
|50-day moving average||$12.03|
|200-day moving average||$12.2243|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$0.44|
Compare share trading platforms
Is it a good time to buy Neuren Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Neuren Pharmaceuticals price performance over time
|1 week (2023-11-22)||-0.46%|
|1 month (2023-10-30)||44.20%|
|3 months (2023-08-30)||16.14%|
|6 months (2023-05-30)||9.78%|
|1 year (2022-11-30)||88.00%|
|2 years (2021-11-30)||735.56%|
|3 years (2020-11-30)||1,142.98%|
|5 years (2018-11-30)||989.86%|
Is Neuren Pharmaceuticals under- or over-valued?
Valuing Neuren Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Neuren Pharmaceuticals 's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Neuren Pharmaceuticals 's P/E ratio
Neuren Pharmaceuticals 's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 34x. In other words, Neuren Pharmaceuticals shares trade at around 34x recent earnings.
That's relatively high compared to, say, the P/E ratio for the ASX over the 12 months to December 2019 (32.14). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Neuren Pharmaceuticals 's EBITDA
Neuren Pharmaceuticals 's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $54.8 million (£0.0 million).
The EBITDA is a measure of a Neuren Pharmaceuticals 's overall financial performance and is widely used to measure a its profitability.
Neuren Pharmaceuticals financials
|Revenue TTM||$78.3 million|
|Operating margin TTM||76.51%|
|Gross profit TTM||$2.7 million|
|Return on assets TTM||51.8%|
|Return on equity TTM||88.06%|
|Market capitalisation||$1.9 billion|
TTM: trailing 12 months
Neuren Pharmaceuticals share dividends
We're not expecting Neuren Pharmaceuticals to pay a dividend over the next 12 months.
Have Neuren Pharmaceuticals 's shares ever split?
Neuren Pharmaceuticals 's shares were split on a 1:20 basis on 21 November 2017. So if you had owned 20 shares the day before the split, the next day you would own 1 share. This wouldn't directly have changed the overall worth of your Neuren Pharmaceuticals shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Neuren Pharmaceuticals shares which in turn could have impacted Neuren Pharmaceuticals 's share price.
Neuren Pharmaceuticals share price volatility
Over the last 12 months, Neuren Pharmaceuticals 's shares have ranged in value from as little as $6.72 up to $15.53. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (AU average) beta is 1, while Neuren Pharmaceuticals 's is 1.601. This would suggest that Neuren Pharmaceuticals 's shares are more volatile than the average for this exchange and represent, relatively speaking, a higher risk (but potentially also market-beating returns).
Neuren Pharmaceuticals overview
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. Neuren Pharmaceuticals Limited was incorporated in 2001 and is based in Camberwell, Australia.
Stocks similar to Neuren Pharmaceuticals
Neuren Pharmaceuticals in the news
Frequently asked questions
More guides on Finder
How to buy OpenAI stock in Australia
Looking to jump on the AI bandwagon? Here's how you can invest in ChatGPT and its parent company OpenAI from Australia.
Best performing stocks on the ASX in 2023 (Updated weekly)
Looking for the best performing stocks in Australia? We update this list weekly.
Cryptocurrency ETFs explained: A simple guide for investors (2023)
If you’re looking for ways to gain exposure to Bitcoin and other digital currencies, cryptocurrency ETFs could be worth exploring. Find out what crypto ETFs are and how they work in this introductory guide.
How to buy Gol Linhas Aereas Inteligentes SA ADR (GOL) shares in Australia
Steps to owning and managing Gol Linhas Aéreas Inteligentes SA shares from Australia.
How to buy Microsoft (MSFT) shares in Australia
Steps to owning and managing Microsoft shares from in Australia.
A beginner’s guide to Lego investing
Looking for alternative investments? With a ROI of up to 3,593% lego may be worth considering. Read on to find out which lego sets are worth the investment.
The cheapest stock brokers in Australia (Nov 2023)
Find cheap stock brokerage in Australia when buying and selling shares on the ASX and other international exchanges.
What is the money market?
Learn about the money market and everyday consumer money market products.
Is investing in crowdfunding a safe investment?
Equity crowdfunding offers a unique opportunity for investors and for Australian startups, but Australia’s regulatory framework surrounding crowdfunding still lags behind the rest of the world.
The best trading platforms in Australia for 2023
Follow these tips to find the best share trading platform for you.
Ask an Expert